[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy]

Nihon Yakurigaku Zasshi. 2005 Nov;126(5):353-7. doi: 10.1254/fpj.126.353.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Resorption / drug therapy
  • Calcitriol / antagonists & inhibitors
  • Cells, Cultured
  • Clinical Trials as Topic
  • Diphosphonates / pharmacology
  • Diphosphonates / therapeutic use*
  • Disease Models, Animal
  • Geranyltranstransferase / antagonists & inhibitors
  • Humans
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / etiology*
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Neoplasms / complications*
  • Osteoclasts / cytology
  • Osteoclasts / drug effects
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid
  • Geranyltranstransferase
  • Calcitriol